Compare ADMA Biologics Inc (ADMA) vs NetFlix Inc (NFLX) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Netflix (NFLX) trades at $76.02, down 2.1% amid a bearish technical trend, though fundamentals remain strong with 2025 revenue of $45.18B and net income of $10.98B. The stock is near its 52-week low, with support at $75 and resistance at $77. Recent Q1 2026 earnings beat expectations with EPS of $1.23 versus $0.76 expected, highlighting robust operational performance despite market pessimism.

The outlook is mixed: strong fundamentals and a consensus price target of $114.75 suggest 51% upside, but technical weakness and competitive pressures pose risks. Investors should weigh the company's high ROE of 48.5% and scaling ad business against market sentiment and recent stock declines.